109384-26-1

Basic information

• Product Name: Tert-butyl 4-methyl-3-oxopiperazine-1-carboxylate ,98%
• Synonyms: Tert-butyl 4-methyl-3-oxopiperazine-1-carboxylate ,98%;Tert-Butyl 4-methyl-3-oxopiperazine-1-carboxylate;1-Piperazinecarboxylic acid, 4-methyl-3-oxo-, 1,1-dimethylethyl ester;4-Methyl-3-oxo-piperazine-1-carboxylicacidtert-butylester;1-tert-Butoxycarbonyl-4-methyl-3-oxopiperazine;1-Boc-4-methyl-3-oxopiperazine, 98%
• CAS NO: 109384-26-1
• Molecular Formula: C₁₀H₁₈N₂O₃
• Molecular Weight: 214
• Mol File: 109384-26-1.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Tert-butyl 4-methyl-3-oxopiperazine-1-carboxylate ,98%(CAS DataBase Reference)
• NIST Chemistry Reference: Tert-butyl 4-methyl-3-oxopiperazine-1-carboxylate ,98%(109384-26-1)
• EPA Substance Registry System: Tert-butyl 4-methyl-3-oxopiperazine-1-carboxylate ,98%(109384-26-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 109384-26-1(Hazardous Substances Data)

Usage

Chemical Properties

Colorless to white liquid or solid

Upstream product

• 5625-67-2 2-Ketopiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 76003-29-7 4-(t-butyloxycarbonyl)piperazin-2-one 
• 74-88-4 methyl iodide 
• 74-83-9 methyl bromide 

Downstream Products

• 109384-27-2 1-methylpiperazin-2-one hydrochloride 
• 59702-07-7 1-methylpiperazin-2-one 
• 1042904-08-4 C₃₃H₃₉F₂N₃O₄ 
• 194350-88-4 4-methyl-3-oxopiperazin-1-ium monotrifluoroacetate 

Relevant articles and documents

2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY

Compound of formula (I′) or (I′′) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.

Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

A series of β-amino amide containing substituted piperazine-2-one derivatives was synthesized and evaluated as inhibitors of dipeptidyl pepdidase-4 (DPP-4) for the treatment of type 2 diabetes. As results of intensive SAR study of the series, (R)-4-[(R)-3-amino-4-(2,4,5-trifluorophenyl)- butanoyl]-3-(t-butoxymethyl)-piperazin-2-one (DA-1229) displayed potent DPP-4 inhibition pattern in several animal models, was selected for clinical development.

Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors

Guided by structure-based design, we synthesized two novel series of potent inhibitors of BACE1 and generated extensive SAR around both the prime and non-prime side binding pockets. The key feature of both series is a cyclic amine motif specifically crafted to achieve interactions with both the flap and with the S2′ pocket.